Common Contracts
4 similar Securities Purchase Agreement contracts by Generex Biotechnology Corp
6% SECURED CONVERTIBLE DEBENTURE DUE JANUARY 27, 2007Securities Purchase Agreement • December 15th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), is designated as its 6% Convertible Debenture, due January 27, 2007 (the “Debenture”).
6% SECURED CONVERTIBLE DEBENTURE DUE SEPTEMBER 16, 2006Securities Purchase Agreement • October 31st, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE is one of a series of duly authorized and issued 6% Secured Convertible Debentures of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), designated as its 6% Convertible Debenture, due September 16, 2006 (the “Debenture(s)”).
6% SECURED CONVERTIBLE DEBENTURE DUE DECEMBER 8 2006Securities Purchase Agreement • September 9th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE is one of a series of duly authorized and issued 6% Secured Convertible Debentures of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), designated as its 6% Convertible Debenture, due December 8, 2006 (the “Debenture(s)”).
6% SECURED CONVERTIBLE DEBENTURE DUE SEPTEMBER 16, 2007Securities Purchase Agreement • July 15th, 2005 • Generex Biotechnology Corp • Pharmaceutical preparations • New York
THIS DEBENTURE is one of a series of duly authorized and issued 6% Secured Convertible Debentures of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), designated as its 6% Convertible Debenture, due September 16, 2007 (the “Debenture(s)”).
